RAC1 and breast cancer: It has been reported that the expression of three miRNAS—miR-30a-3p, miR-30c, and miR-182—was associated with a better response to tamoxifen and a longer progression free survival (p < 0.01) in 246 ER positive advanced BC patients; however, only miR-30c was an independent predictor (p < 0.01), and a global pathway test predicted relation between miR-30c and both HER and RAC1 (Ras-related C3 botulinum toxin substrate 1 precursor) signaling pathways [60].